Search Result

Pathways Recommended:	Anti-infection

Results for "

SARSCoV-2 infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (2) Akt (3) Angiotensin-converting Enzyme (ACE) (10) Antibiotic (11) Apoptosis (6) Autophagy (20) Bacterial (3) Casein Kinase (1) CaSR (1) Cathepsin (3) CDK (3) CMV (1) COX (1) Dengue Virus (1) Deubiquitinase (3) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (10) Drug Metabolite (5) E1/E2/E3 Enzyme (1) EGFR (2) Endogenous Metabolite (6) Enterovirus (2) Environmental Pollutants (1) ERK (3) Filovirus (1) Flavivirus (2) FXR (4) G protein-coupled Bile Acid Receptor 1 (2) Glycosidase (1) Glycosyltransferase (1) HBV (1) HCV (2) HDAC (1) Histamine Receptor (1) Histone Demethylase (2) Histone Methyltransferase (2) HIV (15) IFNAR (3) Influenza Virus (4) Integrin (1) Interleukin Related (6) Isotope-Labeled Compounds (10) Lactate Dehydrogenase (2) MAP3K (2) MDM-2/p53 (2) MEK (2) Microtubule/Tubulin (1) MMP (1) nAChR (1) NF-κB (3) NOD-like Receptor (NLR) (2) Nucleoside Antimetabolite/Analog (1) P-glycoprotein (1) p38 MAPK (2) PAI-1 (1) Parasite (17) PKC (2) PROTACs (5) Proteasome (1) Proton Pump (1) Reference Standards (9) RIG-I-like receptor (RLR) (1) RSV (1) SARS-CoV (156) Sec61 (2) Ser/Thr Protease (6) Sirtuin (1) STING (1) TAM Receptor (1) TGF-β Receptor (1) TNF Receptor (3) Toll-like Receptor (TLR) (20) VEGFR (2) Virus Protease (27)
By Research Areas:	Cancer (36) Cardiovascular Disease (3) Endocrinology (1) Infection (150) Inflammation/Immunology (18) Metabolic Disease (14) Neurological Disease (3)
Click Chemistry:	Alkynes (1)

168

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17589

Chloroquine phosphate Maximum Cited Publications 1191 Publications Verification	Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic	Infection Inflammation/Immunology Cancer
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-B1370

Hydroxychloroquine sulfate 85+ Cited Publications HCQ sulfate	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection Cancer
Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits *SARS-CoV-2* infection in vitro .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Bacterial Antibiotic	Infection
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-17589B

Chloroquine dihydrochloride Maximum Cited Publications 1191 Publications Verification	Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic	Infection Inflammation/Immunology Cancer
Chloroquine dihydrochloride is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine dihydrochloride is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-B0372A

Bromhexine hydrochloride 3 Publications Verification	SARS-CoV Autophagy HIV	Metabolic Disease
Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC₅₀ of 0.75 μM. Bromhexine hydrochloride can prevent and manage *SARS-CoV-2* infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions .

HY-19727A

FOY 251 2 Publications Verification	Ser/Thr Protease SARS-CoV	Metabolic Disease
FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor . FOY 251 inhibits SARS-CoV-2 infection in cells assay .

HY-156651

Zevotrelvir EDP-235	SARS-CoV Virus Protease	Infection
Zevotrelvir (EDP-235) is a coronavirus inhibitor that can inhibit 229E hCoV and the SARS-CoV-2 3C-like (3CL) protease (IC₅₀ <0.1 mM). Zevotrelvir can be used in research on coronavirus infections .

HY-138113

Pyrrothiogatain 1 Publications Verification	DNA/RNA Synthesis Interleukin Related TNF Receptor Angiotensin-converting Enzyme (ACE) SARS-CoV	Infection Inflammation/Immunology Cancer
Pyrrothiogatain is a transcription factor GATA3 inhibitor with an IC₅₀ of 54.7 μM. Pyrrothiogatain inhibits the DNA-binding activity of GATA3 and inhibits the T helper 2 (Th2) cell differentiation and expression of Th2 cytokines. Pyrrothiogatain shows anti-infection effect by inhibiting ACE2 expression. Pyrrothiogatain can be used for the researches of inflammation, immunology, infection and cancer, such as colon cancer and SARS-CoV-2 infection .

HY-137958A

Bemnifosbuvir 4 Publications Verification AT-511	HCV SARS-CoV	Infection
Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₉₀=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity .

HY-153228

Pomotrelvir 1 Publications Verification PBI-0451	SARS-CoV	Infection
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (M ^pro), with an IC₅₀ of 24 nM for wild-type SARS-CoV-2 M ^pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .

HY-161177

PROTAC SARS-CoV-2 3CLPro degrader 2	PROTACs SARS-CoV Virus Protease	Infection
PROTAC KRAS G12D degrader 2 is a peptidomimetic PROTAC specifically targeting the dimeric SARS-CoV-2 3CL ^Pro protein. PROTAC KRAS G12D degrader 2 inhibits SARS-CoV-2 3CLPro with an IC₅₀ of 21.2 μM. PROTAC KRAS G12D degrader 2 specifically binds to the active site of SARS-CoV-2 3CL ^Pro. PROTAC KRAS G12D degrader 2 reduces protein levels of SARS-CoV-2 3CL ^Pro without affecting cell viability. PROTAC KRAS G12D degrader 2 can be used for the study of viral infections in Coronavirus genera .

HY-N3389

Licoisoflavone A 2 Publications Verification	SARS-CoV Sirtuin CDK Apoptosis	Infection Metabolic Disease Cancer
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on *SARS-CoV-2* infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and *SARS-CoV-2* infection .

HY-145592

Ruzotolimod RO7020531; RG7854	Toll-like Receptor (TLR) SARS-CoV HBV	Infection
Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or *SARS-CoV-2* .

HY-171160

WYFA-15	SARS-CoV	Infection
WYFA-15 is a sphingomyelin synthase 1 (SMS1) inhibitor that protects mice against lethal SFTSV infection and reduce *SARS-CoV-2* replication and pathogenesis. WYFA-15 can be utilized in anti-virus research .

HY-161844

Virapinib	SARS-CoV Dengue Virus	Infection
Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against *SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus* infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection .

HY-136597

Remdesivir O-desphosphate acetonide impurity 3 Publications Verification	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-P11032

Mp-4D7-pF2	SARS-CoV Virus Protease	Infection
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 main protease inhibitor with an IC₅₀ of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .

HY-B1370B

(R)-Hydroxychloroquine (R)-HCQ	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection
(R)-Hydroxychloroquine is the enantiomer of Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-179088

AVI-6451	SARS-CoV	Infection
AVI-6451 is a novel orally effective *SARS-CoV-2* Mac1 (IC₅₀ = 28 nM) inhibitor. AVI-6451 can reduce viral load. AVI-6451 can be used for research on viral infections .

HY-B1370A

(S)-Hydroxychloroquine (S)-HCQ	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection
(S)-Hydroxychloroquine ((S)-HCQ) is the enantiomer of Hydroxychloroquine . Hydroxychloroquine, a synthetic antimalarial agent, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro .

HY-131262

Hydroxychloroquine Impurity E 4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol	SARS-CoV Toll-like Receptor (TLR)	Others
Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits *SARS-CoV-2* infection in vitro .

HY-W031727S

Hydroxychloroquine-d4-1 sulfate	Isotope-Labeled Compounds Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection Cancer
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-176232

BBH-4	SARS-CoV	Infection
BBH-4 is a *SARS-CoV-2* major protease (MPro) inhibitor. BBH-4 can be used in SARS-CoV-2 infection research .

HY-175461

AVI-4206	SARS-CoV	Infection
AVI-4206 is a selective Mac1 inhibitor with an lC₅₀ of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of *SARS-CoV-2* infection. AVI-4206 can be used the study of *SARS-CoV-2* infection .

HY-174373

SARS-CoV-2-IN-113	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SARS-CoV-2-IN-113 (Compound 24) is a sulfonohydrazide derivative against *SARS-CoV-2* infection with an IC₅₀ of 8.320 μM. SARS-CoV-2-IN-113 exerts potent antiviral effects by inhibiting the entry and replication of *SARS-CoV-2, and downregulating the expression of genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113* has high selectivity and low cytotoxicity, and can be used in the research of SARS-CoV-2 .

HY-146379

SARS-CoV-2-IN-19	DNA/RNA Synthesis SARS-CoV	Infection
SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .

HY-174251

(±)-Tuaimenal A	SARS-CoV Virus Protease	Infection
(±)-Tuaimenal A ((+)-1) is a secondary metabolite and a derivative of Sesamol (HY-N1417). (±)-Tuaimenal A has potent inhibitory activity against SARS-CoV-2 3CLpro with an IC₅₀ of 33.3  μM. (±)-Tuaimenal A can be used for SARS-CoV-2 infection research .

HY-178188

TPG-20A	SARS-CoV	Infection
TPG-20A is a *SARS-CoV-2* main protease inhibitor with an IC₅₀ of 27.8 nM. TPG-20A also inhibits MERS-CoV main protease. TPG-20A can be used for the research of infection, such as SARS-CoV-2 .

HY-168916

Jun13296	SARS-CoV Virus Protease
Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC₅₀ = 0.13 µM, K_i = 8.8 nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir (HY-138687)-resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model .

HY-175029

ALG-097558	SARS-CoV Virus Protease	Infection
ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various *SARS-CoV-2* variants as well as other human coronaviruses (HCoVs) such as *SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC₅₀s* of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].

HY-175344

TMP1	SARS-CoV Virus Protease Ser/Thr Protease	Infection Inflammation/Immunology
TMP1 is an orally active bispecific inhibitor of M pro (IC₅₀ = 312.5 nM)/TMPRSS2 (IC₅₀ = 1.28 μM, K_D = 10.10 μM). TMP1 exhibits broad protection against different *SARS-CoV-2* variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, *SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection* by *SARS-CoV-2* escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research .

HY-173148

TKB272	SARS-CoV	Infection
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of *SARS-CoV-2. It effectively blocks the infection* and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC₅₀ of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC₅₀ as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC₅₀ of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .

HY-178156

DHODH-IN-31	Dihydroorotate Dehydrogenase SARS-CoV	Infection
DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2 .

HY-19727

FOY 251 free base	Ser/Thr Protease SARS-CoV	Infection Metabolic Disease
FOY 251 free base, an anti-proteolytic active metabolite of Camostate (HY-13512), acts as a proteinase inhibitor . FOY 25 free base inhibits SARS-CoV-2 infection in cells assay .

HY-172350

WEHI-P8	SARS-CoV Virus Protease Interleukin Related	Infection
WEHI-P8 is an orally active *SARS-CoV-2* papain-like protease (PLpro) inhibitor with an IC₅₀ of 12 nM and a K_d of 9.0 nM. WEHI-P8 reduces viral load, body weight loss, pulmonary inflammation, immune cell infiltration and pro-inflammatory mediator levels in SARS-CoV-2-infected mice. WEHI-P8 prevents pulmonary hemorrhage, immune cell infiltration, fibrotic remodeling and neuroinflammation, and improves cognitive function in a mouse model of post-acute sequelae of SARS-CoV-2 infection (PASC). WEHI-P8 is applicable for the research of COVID-19 and PASC .

HY-W031727S1

Hydroxychloroquine-d5	Autophagy SARS-CoV Toll-like Receptor (TLR) Parasite	Cancer
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Antibiotic HIV SARS-CoV	Infection
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-175712

SARS-CoV-2 Mpro-IN-47	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-47 is an orally active SARS-CoV-2 Mpro reversible covalent Inhibitor. SARS-CoV-2 Mpro-IN-47 shows potent antiviral activity against several clinical variants of SARS-CoV-2. SARS-CoV-2 Mpro-IN-47 can be used for the research of infection, such as SARS-CoV-2 .

HY-178435

SARS-CoV-2 Mpro-IN-48	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-48 is a potent *SARS-CoV-2* main protease inhibitor with an IC₅₀ of 21.1 nM. SARS-CoV-2 Mpro-IN-48 exhibits potent antiviral activity against the SARS-CoV-2 JN.1 variant. SARS-CoV-2 Mpro-IN-48 can be used for the research of infection, such as COVID-19 .

HY-173575

SARS-CoV-2 3CLpro-IN-31	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC₅₀ value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection .

HY-163713

SARS-CoV-2-IN-89	SARS-CoV	Infection
SARS-CoV-2-IN-89 (Compound 2) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-162604

SARS-CoV-2-IN-90	SARS-CoV	Infection
SARS-CoV-2-IN-90 (compound 3i) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .

HY-179102

SARS-CoV-2 Mpro-IN-51	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-51 (compound 4) is a SARS-CoV-2 Mpro inhibitor (IC₅₀ = 26 nM). SARS-CoV-2 Mpro-IN-51 has inhibitory effects on the triple mutant L50F/E166A/L167F. SARS-CoV-2 Mpro-IN-51 can be used for research on viral infections .

HY-157305

Jun11165	SARS-CoV	Infection
Jun11165 is a SARS-CoV-2 PL ^pro inhibitor (IC₅₀ ≤ 0.6 μM), which inhibits SARS-CoV-2 with an EC₅₀ value of ≤ 6 μM. Jun11165 can be used in the research of viral infections .

HY-178772

SARS-CoV-2 Mpro-IN-50	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-50 (Compound 30) is a noncovalent SARS-CoV-2 Mpro inhibitor with an IC₅₀ of 14  nM. SARS-CoV-2 Mpro-IN-50 is also a pan-CoV Mpro inhibitor with IC₅₀s of 20-190 nM for SARS-CoV-1 Mpro, 229E Mpro, HKU1 Mpro, MERS Mpro, NL63 Mpro and OC43 Mpro. SARS-CoV-2 Mpro-IN-50 has significant antiviral activity against the SARS-CoV-2 omicron variant (EC₅₀: 22  nM). SARS-CoV-2 Mpro-IN-50 can be used for coronavirus infections research .

HY-146381

SARS-CoV-2-IN-20	SARS-CoV	Infection
SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL ^pro. 3CL ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

Cat. No.	Product Name	Type

HY-138794G

XL177A

Fluorescent Dyes

XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

Cat. No.	Product Name	Type

HY-138794G

XL177A

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P5522A

TriDAP dihydrochloride 1 Publications Verification L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride	NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV	Infection Inflammation/Immunology
TriDAP dihydrochloride (L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride) is a NOD1 agonist with a K_d value of 34.5 μM. TriDAP dihydrochloride enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP dihydrochloride downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP dihydrochloride decreases IκBα levels and increases p65 levels. TriDAP dihydrochloride induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits *SARS-CoV-2* replication in lung epithelial cells. TriDAP dihydrochloride increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP dihydrochloride can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and *SARS-CoV-2* infection .

HY-P11032

Mp-4D7-pF2	SARS-CoV Virus Protease	Infection
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 main protease inhibitor with an IC₅₀ of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .

HY-P5522

TriDAP L-Ala-γ-D-Glu-meso-diaminopimelic acid	NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV	Infection Inflammation/Immunology
TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1 agonist with a K_d value of 34.5 μM. TriDAP enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits *SARS-CoV-2* replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and *SARS-CoV-2* infection .

HY-P10975

P9R	SARS-CoV Influenza Virus Enterovirus	Infection
P9R is an antiviral peptide. P9R has broad-spectrum antiviral activities against the coronaviruses (SARS-CoV-2, MERS-CoV and *SARS-CoV), A(H1N1)pdm09, A(H7N9) virus, and rhinovirus. P9R directly binds to viruses and inhibits virus-host endosomal acidification. P9R significantly protects mice from A(H1N1)pdm09 infection* without generating drug-resistant virus. P9R can be used for pH-dependent respiratory viruses research .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-P11464

SARS-CoV-2 Spike receptor binding domain, RBD (371-394)	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SARS-CoV-2 Spike receptor binding domain, RBD (371-394) is a peptide from *SARS-CoV-2* spike receptor-binding domain. SARS-CoV-2 spike protein receptor-binding domain binds to ACE2. SARS-CoV-2 Spike receptor binding domain, RBD (371-394) can be used in the research of SARS-CoV-2 infection .

HY-P11470

Conofurin-Delta	nAChR SARS-CoV	Infection
Conofurin-Delta is a potent α7 nAChR inhibitor with an IC₅₀ of 177 nM. Conofurin-Delta also inhibits α9α10 nAChR with an IC₅₀ of 98.1 nM. Conofurin-Delta may be used in *SARS-CoV-2* infection research .

HY-P10466A

KZR-8445 TFA	Sec61 SARS-CoV Interleukin Related TNF Receptor IFNAR	Infection Inflammation/Immunology
KZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits *SARS-CoV-2* replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection .

HY-P10466

KZR-8445	Sec61 SARS-CoV Interleukin Related TNF Receptor IFNAR	Infection Inflammation/Immunology
KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits *SARS-CoV-2* replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection .

HY-P11579

TLP-3	SARS-CoV	Infection
TLP-3, Temporin L (HY-P2523) analogue, is a *SARS-CoV-2* main protease (Mpro) inhibitor with an IC₅₀ of 7.0 μM. TLP-3 inhibits protease activity through stabilizing hydrogen bonding and hydrophobic interactions with key enzyme residues. TLP-3 can be used for the research of ARS-CoV‑2 infection .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-P990816

Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) reacts with the N-terminal domain (NTD) in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) can be used for the detections of flow cytometry and ELISA in SARS-CoV-2 infection .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

HY-P991491

VIR-7229	SARS-CoV Influenza Virus	Infection
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992282

Anti-Nucleocapsid Antibody (N-P10)	SARS-CoV	Infection
Anti-Nucleocapsid Antibody (N-P10) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonal antibody. Anti-Nucleocapsid Antibody (N-P10) can be used for research on SARS-CoV-2 infection .

HY-P992283

Anti-Nucleocapsid Antibody (N-P11)	SARS-CoV	Infection
Anti-Nucleocapsid Antibody (N-P11) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonal antibody. Anti-Nucleocapsid Antibody (N-P11) can be used for research on SARS-CoV-2 infection .

HY-P992281

Anti-Nucleocapsid Antibody (N-18)	SARS-CoV	Infection
Anti-Nucleocapsid Antibody (N-18) is an antibody targeting Nucleocapsid, a structural protein of coronaviruses. Anti-Nucleocapsid Antibody (N-18) is applicable to studies on SARS-CoV-2 infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 26 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	Human Gut Microbiota Metabolites Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing *SARS-CoV-2* infection. Orally active .

HY-110066

(Z)-Guggulsterone 5+ Cited Publications	Classification of Application Fields Commiphora myrrha (Nees) Engl. Plants Burseraceae Disease Research Fields Steroids Source Classification Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and *SARS-CoV-2* infection .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Infection Microorganisms Polyphenols Disease Research Fields Source Classification	Bacterial Antibiotic
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-B1513

α-Cyclodextrin 2 Publications Verification	Structural Classification Zea mays L. Polysaccharides Classification of Application Fields Gramineae Other Diseases Plants Disease Research Fields Saccharides Source Classification	Environmental Pollutants SARS-CoV Microtubule/Tubulin
α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against *SARS-CoV-2* infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids .

HY-N0891

Tubeimoside II Tubeimoside-B	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	EGFR TGF-β Receptor RIG-I-like receptor (RLR) SARS-CoV
Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with K_d values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against *SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections*, skin tumors, and sarcoma 180 .

HY-N3389

Licoisoflavone A 2 Publications Verification	Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones Source Classification	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on *SARS-CoV-2* infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and *SARS-CoV-2* infection .

HY-W196368

Thymohydroquinone	Structural Classification Nigella sativa L. Ranunculaceae Phenols Polyphenols Plants Source Classification	COX SARS-CoV
Thymohydroquinone is a COX-2 inhibitor and anti-SARS-CoV-2 agent that induces cytotoxicity, antiproliferative effects and inhibits tumor growth. Thymohydroquinone cannot scavenge superoxide radicals via σ (hydrogen atom transfer) and π-π attacks with superoxide anions. Thymohydroquinone can be used in research related to squamous cell carcinoma, fibrosarcoma and coronavirus disease 2019 (SARS-CoV-2 infection) .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Disease markers Endogenous metabolite Steroids Source Classification	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-126419

Kobophenol A	Infection Classification of Application Fields Cyperaceae Phenols Polyphenols Plants Disease Research Fields Source Classification Carex kobomugi Ohwi	SARS-CoV PKC
Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC₅₀ of 1.81 μM and inhibits *SARS-CoV-2* viral infection in cells with an EC₅₀ of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC₅₀ of 52 µM .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Phenols Polyphenols Endogenous metabolite Source Classification	Antibiotic HIV SARS-CoV
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-110066R

(Z)-Guggulsterone (Standard)	Commiphora myrrha (Nees) Engl. Plants Burseraceae Steroids Source Classification	Reference Standards Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-N10109A

Gallinamide A TFA	Natural Products Microorganisms Source Classification	SARS-CoV Parasite Cathepsin
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC₅₀: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC₅₀: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC₅₀: 50 nM) .

HY-N14351

Ferrocin A	Natural Products Microorganisms Source Classification	SARS-CoV Bacterial Antibiotic
Ferrocin A is a lipopeptide compound that targets the *SARS-CoV-2* RNA-dependent RNA polymerase (nsp12). Ferrocin A can stably bind to nsp12, and as an iron-chelating peptide, it reduces the concentration of free iron in the environment via complexation, thereby inhibiting bacterial growth by repressing the acquisition of essential metal cations. As an iron-chelating antiviral molecule, Ferrocin A may be used in studies related to COVID-19 and bacterial infections .

HY-N18500

(+)-Adlumidine Adlumidine	Structural Classification Alkaloids Quinoline Alkaloids Plants Papaveraceae Corydalis decumbens (Thunb.) Pers. Source Classification	SARS-CoV Virus Protease
(+)-Adlumidine (Adlumidine) is an isoquinoline alkaloid. (+)-Adlumidine efficiently binds to two key targets of SARS-CoV-2, Mpro and RBD, with IC₅₀ values of 953.86 nM and 9.48 μM, respectively. (+)-Adlumidine exerts significant positive inotropic effects and certain positive chronotropic effects on cultured mouse embryonic cardiomyocytes. (+)-Adlumidine can be used for research on cardiovascular-related diseases and SARS-CoV-2 infection.

HY-134222AR

N-Acetylserine (Standard) N-Acetyl-L-serine (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
N-Acetylserine (Standard) is the analytical standard of N-Acetylserine (HY-134222A). This product is intended for research and analytical applications. N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

Cat. No.	Product Name	Chemical Structure

HY-113478S

Ursodeoxycholic acid-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-17589AS

Chloroquine-d5 1 Publications Verification
Chloroquine-d₅ is deuterium labeled Chloroquine (HY-17589A). Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-17589S1

Chloroquine-d4 phosphate

Chloroquine-d₄ (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-W031727S

Hydroxychloroquine-d4-1 sulfate
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-B1370S

Hydroxychloroquine-d4 sulfate
Hydroxychloroquine-d₄ (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-17589S

Chloroquine-d5 diphosphate

Chloroquine-d₅ (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-W031727S1

Hydroxychloroquine-d5
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-B0372AS

Bromhexine-d3 hydrochloride

Bromhexine-d₃ (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC₅₀ of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions .

HY-W707562

FOY 251-d4
FOY 251-d₄ is the deuterium labeled FOY 251 (HY-19727A). FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor . FOY 251 inhibits SARS-CoV-2 infection in cells assay .

HY-134222AS

N-Acetylserine-d3
N-Acetylserine-d₃ is the deuterium labeled N-Acetylserine (HY-134222A). N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

HY-W777545

4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4
4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d₄ is the deuterium labeled Hydroxychloroquine Impurity E (HY-131262). Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

Cat. No.	Product Name		Classification

HY-181033

(M)-AVI-4773		Alkynes
(M)-AVI-4773 is an orally active, blood-brain barrier permeable coronaviruses M ^Pro inhibitor with an IC₅₀ of 2.5 nM aginst *SARS-CoV-2* M ^Pro. (M)-AVI-4773 produces a rapid onset antiviral effect in mouse models of MERS-CoV and SARS-CoV-2 infection .

Cat. No.	Product Name		Classification

HY-B1513

α-Cyclodextrin 2 Publications Verification		Others
α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against *SARS-CoV-2* infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138794G

XL177A	Deubiquitinase SARS-CoV Histone Demethylase	Cancer
XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including *SARS-CoV-2* variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SARSCoV-2 infection

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products